<DOC>
	<DOCNO>NCT00080015</DOCNO>
	<brief_summary>This Phase II , open-label , multicenter , single-arm , exploratory `` proof concept '' study . Diflomotecan ( 7 mg fix dose ) administer 20-minute IV infusion every 3 week patient sensitive small cell lung cancer ( SCLC ) progressive disease first-line treatment platinum-based regimen .</brief_summary>
	<brief_title>Diflomotecan ( BN80915 ) Administered Once Every 3 Weeks Treating Patients With Sensitive Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Main Documented small cell lung cancer ( SCLC ) Measurable disease One line previous chemotherapy , include platinum analogue , exclude camptothecin analogue , objective response relapse less 3 month Main Uncontrollable brain metastasis Treated investigational drug within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>